Nuvectis Pharma Inc (NAS:NVCT)
$ 6.45 -0.4 (-5.84%) Market Cap: 118.40 Mil Enterprise Value: 98.93 Mil PE Ratio: 0 PB Ratio: 8.44 GF Score: 22/100

Nuvectis Pharma Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 04:25PM GMT
Release Date Price: $13.68 (-0.29%)
Rick Bienkowski
Cantor Fitzgerald & Co. - Analyst

Good afternoon, everyone. Welcome back to the Cantor Global Healthcare Conference. My name is Rick Bienkowski, biotech analyst here on the research team. We are very happy to be hosting Nuvectis Pharmaceuticals for a formal presentation today. And today with us on stage, we have Ron Bentsur, President and CEO of the company. And with that, I will turn it over to Ron.

Ron Bentsur
Nuvectis Pharma, Inc. - Chairman, CEO and President

Thank you very much. I want to thank Cantor for inviting us to present at the conference. It's a pleasure to be here. My name is Ron Bentsur, and I'm the CEO of Nuvectis Pharma. And Nuvectis Pharma is a company that's focused on precision medicine for unmet medical needs in oncology, I will be making some forward-looking statements, so I do encourage anyone who's interested in the company to read our public disclosures and in particular, the risk factors section, which is available in our 2022 10-K.

So with that, let's talk about some key highlights for the company. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot